This conversation starts with Stephen talking about the differences between FGF-21s and discussing why these results are so compelling. He asks Mazen to comment on how he expects to use FGF-21s in practice and Mazen provides a thoughtful, nuanced reply.
At this point, Stephen shifts gears to ask why we do not produce more slides from a given liver sample. He and Mazen agree that they have wondered about this for a while and believe it would strengthen results. Speaking from more of a straight statistical perspective, Roger Green agrees.
Patient, Doctor, KOL, BioPharma, Device, Investors, Patient Advocates
Categories: BioPharma, Diagnostics, Drugs, KOL, Patients Tags:
